Met-HeFT
Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance — Metformin Heart Failure Trial (Met-HeFT), component of DANHEART
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 1,100 patients with HFrEF and diabetes or insulin resistance, metformin was compared with placebo on death, worsening heart failure, myocardial infarction or stroke.
N
1.100
Design
investigator-initiated, multicentre (20 Danish public hospitals), randomised 1:1, double-blind, placebo-controlled, event-driven; 2 × 2 factorial with H-HeFT; metformin 500 mg tablets uptitrated to 1,000 mg twice daily (500 mg twice daily if eGFR 35–60 mL/min/1.73 m²) vs matching placebo, with dose reduction or pausing for declining renal function or acute illness; anticipated mean follow-up 4 years
Endpunkt
Time to first occurrence of the composite of death, hospitalisation with worsening heart failure (including an urgent visit requiring intravenous therapy or metolazone, heart transplantation or LVAD implantation), acute myocardial infarction or stroke